Neurenati Raises $1.38M for Hirschsprung's Disease Therapy

Neurenati Therapeutics Raises $1.38M in Funding

Key Highlights:

• Funding: Neurenati Therapeutics, a biotech company focused on developing therapies for rare diseases, raised $1.38M in funding.
• Investors: Quebec Government and angel investors participated in the funding round.
• Development Focus: The funds will be used to advance NEU-001, a proposed therapy for Hirschsprung's disease, towards clinical trials.

Neurenati Therapeutics' Target Market

• Target Market: Neurenati Therapeutics focuses on developing therapies for rare diseases, with a current focus on Hirschsprung's disease.
• Rare Disease Treatment Providers: Healthcare providers specializing in rare disease treatment, particularly in the field of pediatrics.
• Research and Development Partners: Collaborations with research institutions and organizations working on rare disease therapies.

What Neurenati Therapeutics Needs to Buy

• Clinical Trial Support: Services and partnerships to support the clinical trial process, including regulatory compliance and patient recruitment.
• Research and Development Collaboration: Partnerships with research institutions and organizations to further develop therapies for rare diseases.
• Marketing and Awareness: Assistance in raising awareness about rare diseases and the potential of Neurenati's therapies.